Actually the most successful Biotech IPO this week was ASPX. It's PPS went up (about 10% each day) on the second and third day after their IPO. Deefield and several Institutional Investors already own lots of ASPX shares. ASPX debutted @ 13.25 while ICPT debutted about 14 months ago @ aroud $18.00. It appears that ASPX is trading the same low volume that ICPT did for a year after their debut. My advice (IMO) is to watch this one carefully with an intent to at least start a small position if we see a nice base built over the coming weeks; but this one may trend slowly upward (just like ICPT) even without any PR'S. PPHM now should have the funds and everything needed to do their clinical trials first class and bring BAVI to the market so that long suffering NSCLC patients can get relief.
News 
Market Data 
Discover 
